Subcutaneous Actemra: Ph III GiACTA data

Top-line data from the double-blind, international Phase III GiACTA trial in 251 patients with giant cell arteritis showed that 162 mg subcutaneous Actemra once weekly and every 2 weeks plus a 6-month...